Audit: QRS - MitoQ for Health & Longevity
Audit conducted on 26/08/2026 05:21 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 82 |
| Failed | 0 |
| N/A | 11 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Verified span by span against the ER: protocol cells vs ER lines 384-392, time cells vs ER lines 443 and 171, benefit/risk tiers vs ER headings, gates vs ER lines 333-360, markers vs ER table lines 477-483, qualitative items vs ER lines 487-492. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing is carried over (“only in the subgroup that started stiff”, “no theoretical advantage”, “years of continuous use are untested”, “unresolved kidney signal”). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening; e.g. the ER contraindication “estimated filtration rate below 30 mL/min/1.73 m², stages 4-5” is preserved at the same severity. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | “No measurable vascular benefit in regularly exercising adults” is taken from the ER Potential Risks & Side Effects Low tier, not from Benefit-Modifying Factors. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, study names or expert names appear. Named drugs and supplements (amlodipine, omeprazole, urolithin A, L-Citrulline) all appear in the ER for the same fact. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, quantified, limitation-forward tone matching the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven while remaining accessible; the who-benefits framing is actionable rather than discouraging. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents thresholds and observed findings rather than instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive or clinical-advice phrasing; the Monitoring targets are presented as the ER’s functional ranges. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is stated descriptively (“All trials used a single daily dose”, “Improvements were measured at six weeks”). |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the file; marker 4 uses “the individual’s own baseline”, the ER’s own wording. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are expanded in full (flow-mediated dilation, carotid-femoral pulse wave velocity, alanine aminotransferase, oxidised low-density lipoprotein) rather than abbreviated. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every section is compressed to phrase-level entries; the whole sheet is a small fraction of the ER. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by a full-text scan for second-person pronouns: none present. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes a reader who will measure baseline vascular function, buy a $2-4/day supplement and track seven biomarkers. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Monitoring cadence, empty-stomach dosing and vascular imaging at baseline and three months all presuppose willingness to take on inconvenience and cost. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No general-population simplifications; the sheet retains functional rather than conventional biomarker thresholds. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance explicitly surfaces the signal that matters for this audience: benefit “fading to nothing in regular exercisers”. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Full-text scan found no occurrence of “anti-aging” or “anti-ageing”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology throughout (“antihypertensives”, “cytotoxic chemotherapy”, “gastrointestinal reflux”, “hypersensitivity”). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings verified verbatim: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, the four tier labels, and “Marker”/”Target”/”Why”. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 39 template variable names are present; marker_#* is expanded to markers 1-7 and qualitative_item# to items 1-6, as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template shows no change to any static markup, comment, style rule, footer text, or the website= spans. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section is empty; the Risks High subsection is governed by item 13.5, not by this item. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER’s bold labels verbatim: “Standard chronic dose”, “Best time of day”, “Single versus split dosing” (ER lines 384, 390, 392). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels reuse ER terminology (“Walking capacity” and “Arterial stiffness” are ER benefit headings; “Artery widening” is the ER’s own plain-language rendering at line 161 and 520). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan found no 🟩, 🟥, 🟨 or any other emoji indicator. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Discretionary sections are tightly condensed; the only long blocks (7 biomarkers, 6 qualitative markers) are mandated in full by items 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens on line 2, immediately after <!doctype html> on line 1, and precedes all other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the preceding title text sits outside the YAML block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block sits inside an HTML comment and is not duplicated by any rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values are trimmed and unquoted except duration: "00:02", which contains a colon and therefore requires quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: mitoq_2026-0826-0224_Opus_ER.md (line 4), matching the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (line 5), matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0826-0512 (line 6), correct YYYY-MMDD-HHMM format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: mitoq_2026-0826-0224_Opus_QRS.html (line 9), matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace or unnecessary quoting on any of the nine keys. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | <title>MitoQ for Health & Longevity - Quick Reference Sheet</title> (line 22), with & correctly entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic is “MitoQ for Health & Longevity” (line 417), matching the ER canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | “08/26/2026” (line 421), the MM/DD/YYYY form of qrs_creation_date 2026-0826-0512. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5” (line 425), matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the template’s own subline; no badge, alternate-names line, version stamp or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 518-524) into mechanism, what the trials support, who benefits, what failed, and the safety/duration caveat. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the five statements maps to a distinct ER Conclusion passage (lines 518, 520, 522, 520, 522/524). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “energy-producing compartments”, “artery widening”, “vessel function” instead of mitochondria, flow-mediated dilation and endothelial function; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect size, confidence interval or statistical result appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Taken from the “Populations who should avoid MitoQ” list in the ER Key Interactions & Contraindications section (lines 353-360). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-population bullets are represented, one to one. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the stop_items span (lines 575-583). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All six em-dash rationales are stripped (e.g. “— no human safety data at any dose”, “— unpredictable modulation of treatment response”). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and windows preserved: “below 30 mL/min/1.73 m², stages 4-5” and “outside 2.0-3.0 in the preceding three months”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is not left empty; six contraindications are listed. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Taken from the ER Key Interactions & Contraindications bullet list (lines 333-351). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eight interactions carried over; cytotoxic chemotherapy/radiotherapy is correctly excluded as a contraindication, and the statin bullet is excluded because the ER states “No interaction; complementary … No dose change needed”. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the caution_items span (lines 591-601). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanism, consequence and mitigation clauses are all stripped; only the agent class remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every parenthetical drug list is preserved verbatim (amlodipine/lisinopril/losartan; metformin/insulin/gliclazide; omeprazole/esomeprazole/calcium carbonate; vitamin C/vitamin E/N-acetylcysteine; beetroot juice/L-Citrulline; urolithin A/pyrroloquinoline quinone/nicotinamide riboside). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is not left empty; eight interactions are listed. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (lines 382-408). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and dosing frequency are the three decisive implementation choices; approach-selection and population bullets are secondary. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section provides well over three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content; sub-lines condense ER lines 384, 390 and 392. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Artery widening, walking capacity and arterial stiffness are the only three time-to-effect aspects the ER quantifies. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Artery widening (High tier) leads; the two Medium-tier aspects follow, with the quantified walking-capacity result ahead of the arterial-stiffness result, which the ER notes carries no reported outcome figure (line 173). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content from ER lines 443 and 171. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (Practical Considerations, line 443). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (lines 153-235). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit spans are present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of bare ER benefit headings with no magnitudes, citations or mechanisms. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; FMD percentages, SMDs and confidence intervals from ER lines 163, 181 and 191 are all absent. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER; no sub-section is empty. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (lines 255-311). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk spans are present; risks_high is present and hidden. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of bare ER risk headings; the ⚠️ Conflicted markers and magnitude lines are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No frequencies or severity grades survive; the 35%/27.8% and 40%/33% figures from ER lines 269 and 277 are absent. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER states no risk reaches High (line 261), and risks_high is set to style="display: none" with an empty body (line 613) rather than carrying empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (lines 469-483). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarker table rows are present, with targets and rationales carried over verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated from ER line 473 with the weekly/monthly, three-month and six-to-twelve-month cadence. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (lines 485-492). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present, in ER order. |
Issues 26/08/2026 05:21
Pass rate 100.00%. No issues found.
Issues 26/08/2026 05:18
- 1.2 / 1.3 — Hedge dropped in split-dosing note: [action_3_sub] at lines 485–486 states “splitting offers no advantage”, whereas ER line 392 says “splitting offers no theoretical advantage and is not supported by any trial”; removing “theoretical” strengthens the claim.
- 1.3 / 1.4 — Statins listed as a Key Interaction: Line 602 places “Statins (atorvastatin, rosuvastatin)” inside the Key Interactions decision gate, although ER line 339 states “No interaction; complementary … No dose change needed”, relabelling an explicit non-interaction as a caution.
Fixes 26/08/2026 05:18
- 1.2 / 1.3 — Split-dosing hedge restored: [action_3_sub] changed from “splitting offers no advantage” to “splitting offers no theoretical advantage”, matching the ER’s cautious phrasing.
- 1.3 / 1.4 — Statins removed from Key Interactions: Deleted the “Statins (atorvastatin, rosuvastatin)” item from [caution_items], since the ER records statins as “No interaction; complementary” rather than a caution.